Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies

NK cells have killing activity against leukemic cells and solid cancer cells that escape from T cell recognition because of the low expression level of HLA class I molecules. This characteristic feature of NK cell recognition of target cells in contrast to T cells provides a strategy to overcome tol...

Full description

Saved in:
Bibliographic Details
Published in:Blood reviews 2020-11, Vol.44, p.100678-100678, Article 100678
Main Authors: Tanaka, Junji, Miller, Jeffrey S.
Format: Article
Language:English
Subjects:
ADCC
Animals
BiKE
CAR-NK
Cellular therapy
Hematologic Neoplasms - immunology
Hematologic Neoplasms - therapy
Hematopoietic Stem Cell Transplantation - methods
Humans
Immunotherapy, Adoptive - methods
Killer Cells, Natural - immunology
Killer Cells, Natural - transplantation
KIR
Leukemia - immunology
Leukemia - therapy
NK cell
Transplantation, Homologous - methods
TriKE
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:NK cells have killing activity against leukemic cells and solid cancer cells that escape from T cell recognition because of the low expression level of HLA class I molecules. This characteristic feature of NK cell recognition of target cells in contrast to T cells provides a strategy to overcome tolerance in cancer and leukemia patients. A strong alloreactive NK cell-mediated anti-leukemia effect can be induced in haploidentical hematopoietic stem cell transplantation. Also, NK cells can be expanded by several methods for adoptive immunotherapy for hematological malignancies and other malignant diseases. We review the historical role of NK cells and recent approaches to enhance the functions of NK cells, including ex vivo expansion of autologous and allogenic NK cells, checkpoint receptor blockade, and the use of memory-like NK cells and CAR-NK cells, for treatment of hematological malignancies.
ISSN:0268-960X
1532-1681
DOI:10.1016/j.blre.2020.100678